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Increased Langerhans cell accumulation after mycobacterial stimuli
Aims: To evaluate the role of Langerhans cells (LCs) in
the local activation of leprosy lesions. LCs, acting as
tolerance inducers and immune stimuli, are dendritic
cells recently implicated in cutaneous homeostasis.
The role of LCs in the defence against mycobacterial
infection remains poorly understood.
Methods and results: The number and distribution of
CD1a+ skin cells and HLA-DR and intercellular adhe-
sion molecule (ICAM)-1 expression were analysed in
leprosy skin lesions and in delayed-type hypersensiti-
vity (DTH) tests. The results showed a high number of
LCs in tuberculin and lepromin tests, in tuberculoid
lesions and in the epidermis and dermis during type I
and II reactions. In multibacillary lesions, however, the
number of LCs was consistently low in comparison
with other groups. Increased numbers of LCs were
accompanied by marked HLA-DR and ICAM-1 expres-
sion, suggesting a strong relationship between these
immunological events.
Conclusions: CD1a+ cells are implicated in the local
immunological events taking place after mycobacterial
stimuli and may account for the local activation of all
types of reactional episodes in leprosy.
Keywords: dendritic cells, infection, Langerhans cells, leprosy, Mycobacterium leprae
Abbreviations: BL, borderline leprosy; BT, borderline tuberculoid; CI, conﬁdence interval; CMI, cell-mediated
immunity; DC, dendritic cell; DTH, delayed-type hypersensitivity; EM, erythema multiforme; ENL,
erythema nodosum leprosum; ICAM, intercellular adhesion molecule; IFN, interferon; IL, interleukin; LL,
lepromatous leprosy; mAb, monoclonal antibody; PPD, puriﬁed protein derivative; RR, reversal reaction; TNF,
tumour necrosis factor
Introduction
Leprosy is a chronic infectious disease whose clinical
spectrum is dependent upon the immunological status
of the patient. At the tuberculoid pole, patients
demonstrate well-mounted cell-mediated immunity
(CMI), which, although limiting the number of bacilli
and lesions, accounts for the prominent impairment of
the peripheral nerves. Conversely, the lepromatous
pole is characterized by widespread skin lesions,
unrestricted multiplication of bacilli and an impaired
cellular immune response. Acute inﬂammatory epi-
sodes, designated ‘reactional episodes’ or ‘reactions’,
complicate the clinical course of the disease and are
responsible for even worse neurological damage to the
peripheral nervous system.
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cesses that interrupt the chronic, insidious course of
leprosy. The mechanisms involved in triggering these
processes remain unknown. Reactions are believed to
represent the re-emergence or enhancement of CMI,
which has been either lost or down-regulated during
chronic infection. The mechanisms involved in this
immune reactivation are of great interest and present
an on-going challenge to immunologists.
1
A previous study
2 has shown a direct correlation
between the number of T cells, CD1 and effective
immunity. In this context, a greater number of CD1+
cells was found in the dermal inﬁltrate in tuberculoid
and reversal reaction (RR) lesions, but not in erythema
nodosum leprosum (ENL) lesions. Moreover, in the
same study, the number of CD1a cells within the
epidermis of lepromatous leprosy (LL) and tuberculoid
lesions was not signiﬁcantly different when compared
with that found in normal skin.
CD1 belongs to a family of non-polymorphic,
b2-microglobulin-associated, transmembrane glycopro-
teins that are structurally related to classical major
histocompatibility complex antigen-presenting mole-
cules.
3–5 Recent studies have established the important
role played by CD1 molecules in lipid antigen recogni-
tion by T cells. Mycobacterial cell wall components
such as mycolic acid, lipoarabinomannan and others
are presented by CD1a, B dendritic cells and are
recognized by a, b T cells.
6 It is known that Langerin
exclusively expressed by LCs is an important antigen
uptake receptor for the generation of such T cells.
7
Comprising 1–3% of all epidermal cells, LCs are bone
marrow-derived dendritic cells (DCs) asymmetrically
distributed within the epidermis and other keratinized
and non-keratinized squamous epithelia.
8 LCs initiate
immune responses by capturing and processing foreign
antigens and then emigrating to the regional lymph
nodes, where they present the processed antigen to
naive T cells. It is believed that these cells return to the
skin where they act as inﬂammatory cells.
8,9
Langerhans cells have been implicated in the main-
tenance of cutaneous homeostasis by inducing toler-
ance as well as stimulating immune responses. In
many skin diseases with an enhanced inﬂux of T
lymphocytes, the total number of LCs increases in the
epidermis and decreases after exposure to ultraviolet
rays or toxic substances.
10,11
It has also been demonstrated that tumour necrosis
factor (TNF), in addition to granulocyte macrophage–
colony-stimulating factor and interleukin (IL)-1, are
involved in the LC maturation process. TNF, for the
most part produced in the skin in a number of
inﬂammatory conditions, signiﬁcantly increases the
number of viable LCs while decreasing their apopto-
sis.
12 In this same study, TNF-a induced LCs to produce
interferon (IFN)-inducible protein 10 ⁄ CXCL10, a Th1-
attracting chemokine and IL-12p40.
12 It has been
consistently demonstrated that TNF is up-regulated in
type I and type II reactions.
1 However, the antigen and
the immune T-cell subsets involved in the reactivation
of CMI during these reactions are still unknown.
To obtain more knowledge of the role of epidermal
LCs inthe immuneresponsetoMycobacteriumleprae,the
causative agent of leprosy, and the pathogenic mech-
anisms underlying M. leprae-induced immune responses
in both types of leprosy reactions, a quantitative
analysis of epidermal and dermal CD1a expression in
the biopsy specimens of cutaneous leprosy lesions was
performed using immunohistochemistry. These ﬁndings
were compared with those observed in samples taken
from two mycobacterial skin tests [puriﬁed protein
derivative (PPD) and lepromin] widely known to repre-
sent local CMI against mycobacterial antigens.
Patients and methods
patients
The study was carried out on skin biopsy specimens
taken from the lesions of 94 leprosy patients from the
Leprosy Laboratory, Department of Mycobacterioses,
Oswaldo Cruz Institute, Rio de Janeiro, RJ, Brazil. Skin
biopsy specimens (6 mm in diameter) containing both
epidermis and dermis were obtained by the standard
punch technique, following informed consent.
Patients were classiﬁed clinically according to the
Ridley and Jopling criteria
13 and those selected divided
into four groups: (i) those with type I reaction (RR);
(ii) those with type II reaction [ENL or erythema
multiforme (EM)]; (iii) those with borderline tubercu-
loid leprosy (BT) and (iv) those with multibacillary
leprosy [borderline leprosy (BL) ⁄ LL forms]. In addition,
the biopsy specimens taken from lepromin and PPD+
tests (DTH group) were also included.
immunohistochemical analysis of cd1,h l a - d r
and intercellular adhesion molecule-1
expression in leprosy skin lesions
Biopsy specimens were snap-frozen in liquid nitrogen
until use. Serial sections (6 lm) were acetone ﬁxed at
4 C for 10 min and blocked with normal horse serum
for 30 min (Vector Laboratories, Burlingame, CA, USA)
before incubation with monoclonal antibodies (mAbs).
For assessment of LCs or keratinocytes expressing HLA-
DR and intercellular adhesion molecule (ICAM)-1,
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mAbs antihuman CD1 (1:50), antihuman HLA-DR
(1:25 dilution; Becton Dickinson, Mountain View, CA,
USA) or antihuman ICAM-1 (CD54, 1:25; Immuno-
tech, Marseilles, France) overnight at 4 C. For revela-
tion, biotinylated horse antimouse IgG (1:150; 60 min)
and Vectastain ABC Kit (Vector Laboratories) were
used. As a chromogen, 3-amino-9-ethylcarbazole was
used and slides were counterstained with haematoxy-
lin. Negative controls were performed after omitting the
primary antibody; no labelling was observed.
quantification of cd1 a n dh l a - d re x p r e s s i o n
in leprosy skin lesions
The number of epidermal and dermal cells expressing
CD1 was evaluated using a conventional optical
microscope. In the epidermis, the total number of
CD1+ cells was counted using a large ﬁeld (·40)
objective and the average CD1+ cell count per ﬁeld was
calculated. In the dermis, the number of CD1+ cells
was evaluated by counting their total number in the
whole biopsy section. In each group, data are expressed
as median ± 95% conﬁdence interval (CI).
The relative density of keratinocytes expressing HLA-
DR was semiquantitatively determined, as follows:
(i) absence of stained keratinocytes; (ii) when 25% of
keratinocytes were HLA-DR+; (iii) when 50–75% of
keratinocytes were HLA-DR+ or (iv) when >75%
of keratinocytes were HLA-DR+. In each group, data
are expressed as median ± 95% CI.
In addition, biopsy specimens of all patients with type
II reaction, BT group, multibacillary leprosy (BL ⁄ LL)
group and DTH group were labelled with anti-ICAM-1.
The expression by keratinocytes was qualitatively
evaluated as positive or negative.
statistical analysis
A non-parametric Mann–Whitney test was used to
analyse epidermal and dermal CD1+ cells. Fisher’s test
was used to analyse the semiquantitative density of
keratinocytes expressing HLA-DR. Graph Pad Instat
version 3.01 software (GraphPad Software Inc., San
Diego, CA, USA) was used and P < 0.05 was consid-
ered to be statistically signiﬁcant.
Results
cd1 expression in cutaneous leprosy lesions
Immunohistochemistry for CD1a molecules was per-
formed on biopsy specimens of skin lesions from 12
patients with type I reaction, 33 with type II
reaction, 10 BT patients, 19 multibacillary patients
and 20 lepromin-positive (n = 6) or PPD+ (n = 14)
tests.
All epidermal CD1a+ cells presented a similar
neuronal-like aspect observed in dermal CD1a+ cells
and were most often localized in the suprabasal layers
between keratinocytes (Figure 1A–C). No difference
was observed in the BL ⁄ LL group in comparison with
normal skin.
Quantiﬁcation of epidermal CD1a+ cells showed a
24% increase in patients with a type I reaction
(6.2 ± 1.5) in comparison with patients with a type
II reaction (3.6 ± 1.5; P < 0.05; Figure 2A). When
patients with type I and type II reactions were
compared with the BT group (6.9 ± 1.6), no differ-
ences were observed. However, when compared with
the BL ⁄ LL group (2.5 ± 0.9), the number of epider-
mal CD1a+ cells was 135% and 90% higher (P <
0.0005 and P < 0.005), respectively (Figure 2A).
Data showed that the number of epidermal CD1a+
cells was 121% higher in the BT group (6.9 ± 1.6)
than in the BL ⁄ LL group (2.5 ± 0.9; P < 0.005;
Figure 2A). Moreover, numbers of epidermal CD1a+
cells were 180% and 51% higher, respectively, in the
DTH positive group (7.8 ± 1.2) in comparison with
the BL ⁄ LL group (2.5 ± 0.9; P < 0.0001) and with
type II reactional patients (3.6 ± 1.5; P < 0.0005;
Figure 2A).
Dermal cells expressing CD1a were also evaluated
and quantiﬁed. These cells were aggregated in the
papillary dermis which is often localized around
superﬁcial capillaries (Figure 1D). Although the der-
mal CD1a+ cells also varied in number, their
distribution followed the same pattern as that
observed in the epidermis. That is to say that, on
the one hand, the cell count was higher when tissue
DTH features were prominent, as seen in the BT and
DTH groups and in type I reaction, but moderate in
type II reaction and close to zero in the BL ⁄ LL group
(Figure 1).
When patients with type I and type II reactions
(4.5 ± 4.3 and 4.0 ± 1.7, respectively) were compared
with the BL ⁄ LL group (2.0 ± 0.7), the total number of
dermal CD1a+ cells was 387% and 225% higher
(P < 0.05 and P < 0.005), respectively (Figure 2B).
The number of dermal CD1a+ cells per biopsy specimen
was 250% higher in the BT group (5.0 ± 2.8) than in
the BL ⁄ LL group (2.0 ± 0.7; P < 0.05; Figure 2B). In
addition, the total number of dermal CD1a+ cells was
263% higher in the DTH+ group (3.5 ± 2.9) when
compared with the BL ⁄ LL group (2.0 ± 0.7; P < 0.05;
Figure 2B).
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lesions
To conﬁrm the simultaneous immune activation of the
epidermis in leprosy, lesions expressing HLA-DR and
ICAM-1 molecules were analysed in the keratinocytes
in all samples. Immunohistochemical analysis of
HLA-DR expression was performed on biopsy speci-
mens of skin lesions from 12 patients with type I
reaction, 33 with type II reaction, 10 from the BT
group and 19 from the BL ⁄ LL group.
As previously stated regarding the presence of LCs,
positivity to HLD-DR within the epidermis was also
marked in all cases in which CMI to M. leprae was
clearly developed, but was mild or absent when
effective CMI was lacking, as in the BL ⁄ LL group. In
normal skin, only constitutively positive LCs expressed
HLA-DR (Figure 3A–C).
Semiquantitative analysis of HLA-DR+ epidermal
cells showed that the number of keratinocytes express-
ing HLA-DR was not different for patients with either
type I (3.0 ± 0.7) or type II reactions (3.5 ± 0.4).
When these patients were compared with the BT group
(2.0 ± 0.8), the density of HLA-DR+ keratinocytes was
less in the BL ⁄ LL group (1.0 ± 0.2) than in patients
with type I (3.0 ± 0.7; P < 0.001) or type II reactions
(3.5 ± 0.4; P < 0.0001), or in the BT group (2.0 ±





Figure 1. CD1 expression in leprosy skin lesions. A, a few positive cells in suprabasal localization of ﬂattened epidermis of lepromatous
leprosy ⁄ borderline leprosy patients. B, dendritic cells in upper layers of the thickened epidermis in a type II reaction patient. C, marked positive
dendritic cells in a type I reaction patient. D, numerous positive cells in the dermis of a type II reaction patient. The original magniﬁcation
is shown.
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lesions
An evaluation was also made of the expression of
ICAM-1 on the surface of keratinocytes in the skin
lesions of 33 patients with type II reaction, 10 BT
patients, 19 BL ⁄ LL patients and 20 DTH patients.
Normal skin biopsy specimens were used as controls. In
normal skin and BL ⁄ LL cutaneous lesions, ICAM-1 was
not expressed. The BT and the DTH groups showed
mild to moderate expression of ICAM-1, which rarely
included the entire thickness of the epidermis, but was,
conversely, restricted to two or three foci. In type II
reaction, mild ICAM-1 expression, conﬁned to basal
layers or to no more than two foci of keratinocytes,
could be detected (Figure 3D–F) in each specimen.
Discussion
The skin provides the initial barrier of protection
against the invasion of pathogens and harmful stimu-
lants into the body. In this study, LCs, as deﬁned by
their positivity for CD1a, were found in varying
concentrations within the epidermis, papillary dermis
and granulomas in all samples tested. In the absence of
any other known antigen stimulation, it can be
assumed that the higher concentration of LCs in
reactional episodes is the result of the same immuno-
logical events underway in tuberculoid lesions and
mycobacterial positive skin tests. As previously
reported by Sieling et al.,
2 the number of LCs in the
epidermis within leprosy lesions is closely related to the
extent of the cutaneous cell-mediated immune
response. This increase would be the result of the
recruitment of CD1 precursors from bone marrow or
the adjacent skin.
14
In our study, a signiﬁcant increase in the number of
LCs was observed in both RR and ENL reactional
lesions, in which the LC mean in the epidermis was
similar to that found in tuberculoid lesions. Interest-
ingly, the number of LCs detected in reactional lesions
was also comparable to that detected in the DTH
lesions (lepromin and PPD), suggesting that this effect
is related to mycobacterial antigens and is not leprosy
speciﬁc. It could be hypothesized that even in multi-
bacillary patients in the throes of reaction, the new
M. leprae antigens reaching the skin activate the
cutaneous DCs, which, in turn, trigger new migra-
tory waves of inﬂammatory immune cells responsible
for the appearance of new lesions. In addition to
the LC increase, reactional lesions are characterized
by a dense inﬁltration of newly recruited, activated
macrophages, lymphocytes and polymorphonuclear
leucocytes, which progressively disappear after corti-
costeroid and thalidomide (ENL) therapy. Previous
studies have suggested that RR is triggered by
LC activation.
15 The current study has extended this
hypothesis to ENL lesions. Moreover, it has recently
been demonstrated that LC-like DCs are able to present
non-peptide antigens of M. leprae in a CD1a-restricted
manner. A CD1a-restricted T cell that recognizes
mycobacterial antigens has been identiﬁed as a
CD8+ T cell.
7,16 The role of this T subset in reactional
activation in leprosy requires clariﬁcation. Some









































































































Figure 2. Quantiﬁcation of CD1 expression in leprosy lesions in all
groups studied [biopsy specimens of type I and type II reactions;
tuberculoid (BT) and lepromatous (BL); and lepromin and puriﬁed
protein derivative-positive tests (DTH)]. A, number of CD1+
epidermal cells per ﬁeld. B, total number of CD+ dermal cells.
Median ± 95% CI. A,* P < 0.05; **P < 0.0005; ***P < 0.005;
****P < 0.0001. B,* P < 0.05; **P < 0.005.
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reactional patients whether the lesions were ENL or
EM. Although some studies have demonstrated a few
aspects of CMI reactivation during type II reaction, our
study has strengthened this hypothesis. The histo-
pathological ﬁndings of type II reaction in fact differ
from those seen in RR, whereas vascular changes and
polymorphonuclear inﬁltration predominate in type II
reaction. As in many other inﬂammatory skin diseases,
LCs trigger the immune response, but the pathological
aspects of the lesions depend on the cytokine proﬁle
secreted by the inﬂammatory cells attracted to the
lesion site.
It is now assumed that, during a type II reaction,
higher levels of TNF are secreted locally. TNF-a has
been implicated in the mobilization of LC precursors
from the bone marrow, as well as the maturation of
DCs. In vitro studies have shown that TNF-a signiﬁ-
cantly increases the number of viable LCs by decreasing
their spontaneous apoptosis.
17 On the other hand, TNF
and IL-1B have been reported to increase LC migration,
in this way reducing the number of cells in the
epidermis and increasing cell numbers in the dermis.
18
It is also known that LCs can produce large amounts
of IL-1 and TNF in response to exogenous stimuli
and cytokines.
19 High levels of mRNA TNF expression
have been demonstrated in both types of reactional
lesions.
12,20
The mechanisms regulating the expression of HLA-
DR and ICAM-1 in reactional lesions are not well
understood. In normal skin, KCs express neither HLA-
DR nor ICAM-1 and LCs are the only HLA-DR+ cells.
However, these molecules have been repeatedly shown





Figure 3. HLA-DR and intercellular adhesion molecule (ICAM)-1 expression in leprosy skin lesions. Figures are representative of HLA-DR (A–C)
and ICAM-1 (D–F). A, only the dermal inﬁltrates are labelled in a type II reaction biopsy. B, ﬁfty per cent of keratinocytes are labelled in a
borderline tuberculoid patient. C, marked expression in type I reaction. D, labelled cells along the basal layer (type II reaction). E, two marked foci
in type II reaction. F, the basal layer and addictional foci are stained in a delayed-type hypersensitivity group biopsy specimen. The original
magniﬁcation is shown.
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both types of reaction has conﬁrmed previous studies
demonstrating increased IFN-c mRNA and TNF mRNA
expression in reactional lesions.
21 The correlation
between epidermal and dermal LC numbers suggests
that a dynamic ﬂux of LC streams from the epidermis
toward the dermal venules coexists both in reactional
lesions and in DTH skin tests. Variations in LC num-
bers in the skin have also been found in cutaneous
leishmaniasis. Higher LC numbers have been detected
in localized cutaneous lesions in contrast to the
defensive forms of the disease.
22
In the present study, higher LC numbers in both the
epidermis and dermis were detected in conditions
known to have an established CMI, such as in PPD+
and lepromin-positive tests. In both tests, the injection
of mycobacterial antigens induced a local immune
response in previously sensitized individuals.
The tuberculin reaction has been considered the
prototype of a DTH and has been useful in determining
the cell components of CMI in situ. Injection of PPD into
the skin of lepromatous leprosy patients leads to an
emigration of IFN-c secretion cells into the dermis,
induction of HLA class II by KC, and accumulation of
LCs in the dermis, accompanied by a reduced bacillary
load.
23 Lepromin reaction has been used as an impor-
tant tool to differentiate between tuberculoid and
lepromatous patients, since only the former are lepro-
min positive.
In this study, LC participation in response to
mycobacterial antigens was conﬁrmed by increasing
LC numbers whenever effective CMI was observed in
tissue biopsy specimens. The similar results observed in
RR and ENL strongly support shared common mecha-
nisms of LC activation. The difference between lepro-
matouspatientsandthosegroupswithconspicuousCMI
was statistically signiﬁcant. The increase in LC numbers
was accompanied by HLA-DR and ICAM-1 expression,
suggesting a close relationship between these immuno-
logical events. The immunohistochemical approach
using the antibody to CD1a may therefore be a useful
tool in evaluating the immunological status of leprosy
patients because of its ability to shed more light on the
pathogenic mechanisms involved in RR and ENL.
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